David M. Safley
University of Missouri–Kansas City
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by David M. Safley.
Jacc-cardiovascular Interventions | 2008
David M. Safley; John A. House; Steven P. Marso; J. Aaron Grantham; Barry D. Rutherford
OBJECTIVES This study compared the survival benefit of opening a chronic total occlusion (CTO) of the left anterior descending (LAD), left circumflex (LCX), or right coronary artery (RCA). BACKGROUND Previous analyses demonstrate improved survival following successful percutaneous coronary intervention (PCI) for CTO. METHODS Eligible patients underwent attempted CTO PCI in a single vessel. Procedural success rates were calculated for each vessel. The primary end point was survival at 5 years, compared across target vessel groups stratified by procedural success. RESULTS There were 2,608 patients included. The LAD was the target vessel in 936 (36%), the LCX in 682 (26%), and the RCA in 990 (38%) patients. Angiographic success rates for LAD were 77%, LCX 76%, and RCA 72%. Baseline demographics and comorbidities were well matched, though there were significantly more males in the LCX compared with LAD or RCA groups (80% vs. 75% and 73%, respectively, p = 0.005). Procedural success compared with failure was associated with improved 5-year survival in the LAD (88.9% vs. 80.2%, p < 0.001) group, but not in the LCX (86.1% vs. 82.1%, p = 0.21) and RCA groups (87.7% vs. 84.9%, p = 0.23). In multivariable analysis, CTO PCI success in the LAD group remained associated with decreased mortality risk (HR: 0.61, 95% CI: 0.42 to 0.89). CONCLUSIONS The data suggest that PCI for CTO of the LAD, but not LCX or RCA, is associated with improved long-term survival. This information may assist in selecting patients for attempted CTO PCI.
Jacc-cardiovascular Interventions | 2010
Joshua M. Stolker; Elizabeth M. Mahoney; David M. Safley; Frank B. Pomposelli; Jay S. Yadav; David J. Cohen
OBJECTIVES This study compared health-related quality of life in patients undergoing carotid artery stenting (CAS) versus surgical endarterectomy (CEA). BACKGROUND Carotid artery stenting is approved in the U.S. for treating carotid stenosis in patients at high surgical risk. Whether CAS offers advantages in terms of other patient-centered outcomes is unknown. METHODS We evaluated health-related quality of life in the SAPPHIRE (Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy) trial, which randomized 334 high-risk patients with carotid stenosis to CAS versus CEA. Health status assessments were obtained at baseline; 2 weeks; and 1, 6, and 12 months after revascularization. Generic measures included the Short-Form-36 (SF-36) (0 to 100 scale), general health rating, and EuroQol (EQ-5D). In addition, we used 6 disease-specific modified Likert scales to assess difficulty with walking, eating/swallowing, driving, headaches, neck pain, and leg pain. RESULTS In patients treated according to protocol (n = 159 CAS; n = 151 CEA), CAS patients had better scores at 2 weeks for the SF-36 role physical scale (mean difference: 9.0; 95% confidence interval: 0.9 to 17.1; p = 0.031), but these differences had resolved by 1-month follow-up. For the disease-specific scales, CAS patients reported less difficulty eating/swallowing at 2 weeks, less difficulty driving at 2 weeks, and less neck pain at 2 weeks; each of these differences between groups was no longer present at 1 month. No other scores differed between groups at any time point. CONCLUSIONS Among patients at high surgical risk, CAS was associated with less health status impairment during the first 2 weeks of recovery when compared with CEA. However, these differences had resolved by 1 month after the procedure, and no other differences between revascularization strategies in health-related quality of life were found.
Diabetes and Vascular Disease Research | 2006
David M. Safley; John A. House; Barry D. Rutherford; Steven P. Marso
The objectives of this study were to evaluate angiographic and clinical outcomes among patients with diabetes mellitus (DM) who underwent percutaneous coronary intervention (PCI) for a chronic total occlusion (CTO). We compared them with matched patients undergoing PCI of a non-CTO lesion. All patients had documented DM. Matching was performed using a propensity score for CTO. There were 506 patients with DM and CTO who were matched with a non-CTO group. Results showed that angiographic success rates were lower with CTO (75% vs. 93%, p<0.001). In-hospital major adverse cardiac event (MACE Â death, urgent bypass surgery, Q-wave myocardial infarction or target vessel revascularisation) rates were equivalent (CTO 3.2% vs. non-CTO 2.6%, p=0.57). Survival was not different five years after revascularisation of CTO (75%) vs. non-CTO (79%) (p=0.20). In addition, when DM patients with CTO were analysed according to angiographic success of PCI, there were no significant differences in either in-hospital (success 1.6% vs. failure 2.4%, p=0.7) or 1-year mortality (success 22.2% vs. failure 26.8%, p=0.3). We conclude that PCI of CTO is safe in patients with DM. Angiographic failure is not associated with an increase in MACE rates or mortality as compared to matched nonCTO patients. However, there is not a measurable improvement in survival in this DM-CTO population.
Vascular Medicine | 2011
Kim G. Smolderen; David M. Safley; John A. House; John A. Spertus; Steven P. Marso
Depressive symptoms are known to compromise health status in cardiac disease, but this relationship has not been described in peripheral artery disease (PAD). Depressive symptoms (PHQ-9) and disease-specific health status (Peripheral Artery Questionnaire, PAQ) were assessed in 242 PAD patients undergoing percutaneous transluminal angioplasty (PTA) at baseline and 1 year. Patients were classified by baseline and follow-up depression status (moderate–severe depressive symptoms = PHQ ≥ 10). Changes were categorized as no depression/improvement of depression versus persistent/worsened depression. At baseline, 20% of patients were depressed; at 1 year, 17% of patients experienced persistent/worsened depression. Although this group improved on most PAQ subscales, they improved to a significantly lesser degree than those without depressive symptoms or those who improved by 1 year (p-values < 0.05). Baseline depressive symptoms (Bper 5-point increment = −11.9, 95% CI −15.3, −8.5, p < 0.0001) and changes in depression were independently associated with a decrease in 1-year health status (Bper 5-point increment = −11.7, 95% CI −14.3, −9.2, p < 0.0001). In conclusion, depressive symptoms are associated with less improvement in health status 1 year after undergoing a peripheral endovascular revascularization (PER) as compared with those having no depression or whose depressive symptoms improve. Efforts to improve depression detection and treatment among patients with PAD may improve the health status outcomes of these patients.
American Journal of Cardiology | 2011
Drew S. Allen; Steven P. Marso; Jason B. Lindsey; Kevin F. Kennedy; David M. Safley
Arterial closure devices (ACDs) provide immediate hemostasis, improve comfort, and allow early ambulation after percutaneous coronary intervention (PCI). The aim of this study was to evaluate ACD utilization and post-PCI major bleeding in an unselected cohort. Patients receiving ACDs were propensity matched to those with manual compression to evaluate a primary end point of National Cardiovascular Data Registry (NCDR) major bleeding and a secondary end point of major bleeding stratified by previously developed NCDR bleeding risk categories. Bleeding events that required transfusion, prolonged hospital stays, and/or decreases in hemoglobin ≥3.0 g/dl were included. Length of stay, defined as days after PCI until discharge, was also evaluated. Secondary analysis of bleeding and complication rates between ACD types (suture vs collagen plug) was performed. Five thousand four hundred twenty-one patients underwent PCI, and 2,324 patients (43%) were included in the final propensity matching: 1,162 with ACDs and 1,162 manual compression patients. Major bleeding was reduced in ACD patients compared to those with manual compression (2.4% vs 5.2%, p <0.001), and NCDR high-risk patients receiving ACDs had the greatest reduction in major bleeds (3.1% vs 10.3%, p <0.001). Length of stay (1.9 ± 1.9 vs 2.3 ± 5.3 days, p = 0.007) and pseudoaneurysms (0.3% vs 1.1%, p = 0.028) were decreased in ACD patients. Suture-based devices revealed a lower composite event rate than collagen-plug ACDs (1.4% vs 3.4%, p = 0.048). In conclusion, ACD use is associated with reductions in NCDR major bleeding, length of stay, and pseudoaneurysms in PCI patients.
Diabetes Care | 2006
Steven P. Marso; David M. Safley; John A. House; Todd Tessendorf; Kimberly J. Reid; John A. Spertus
Clinicians use a variety of methods (1,2) to risk stratify patients with acute coronary syndromes (ACSs). Based on elevated risk, patients are often triaged to an aggressive strategy, including early angiography (3,4) and upstream use of intravenous glycoprotein IIb/IIIa inhibitors (5–7). The current American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines for the Management of Patients with Unstable Angina and Non-ST-segment Elevation Myocardial Infarction do not recognize diabetes as a high-risk ACS indicator. Therefore, we sought to clarify the relative risk of diabetes in early and late death in suspected ACS patients. In this study, a prospective registry of consecutive ACS patients with and without diabetes ( n = 864) was used. ACS was diagnosed as either myocardial infarction (8) or unstable angina (9) using standard definitions. Patients with ST-segment elevation myocardial infarction were excluded. All potential unstable angina patients who had a diagnostic angiographic, nuclear, or echocardiographic stress test that excluded obstructive coronary disease or who had an additional diagnostic study confirming an alternative explanation for presentation were excluded. Diabetes was defined by reported history or new antidiabetic therapy initiated during …
Diabetes and Vascular Disease Research | 2005
Steven P. Marso; Joseph W Murphy; John A. House; David M. Safley; William S. Harris
There are few data concerning the relationship between diabetes mellitus, the metabolic syndrome and inflammation following elective percutaneous coronary intervention (PCI). The purpose of this study was to assess basal and peak levels of candidate cytokines in 40 patients undergoing elective PCI. Patients were categorised as having diabetes mellitus, the metabolic syndrome, or neither. Patients with the metabolic syndrome exhibited significantly greater levels of tumour necrosis factor-a over the study period, although this was unrelated to PCI. There was a trend for increased levels of interleukin-6 following PCI, primarily among patients with metabolic syndrome. Basal levels of monocyte chemoattractant protein-1 (MCP-1) were not different among study groups; however, the metabolic syndrome cohort had a trend towards increased circulating levels of MCP-1 after PCI. In this patient population, the metabolic syndrome correlates with a heightened inflammatory response following elective PCI.
Diabetes and Vascular Disease Research | 2005
David M. Safley; Steven P. Marso
Diabetes mellitus has reached epidemic proportions worldwide. Patients with diabetes are at increased risk for acute coronary syndromes, and these syndromes lead to frequent morbidity and cardiovascular mortality. Emerging adjunctive pharmacological strategies coupled with the drug-eluting stent platform have resulted in improved adverse event rates for this high-risk group. This review will concentrate on the historical data associated with acute coronary syndromes in diabetes mellitus, focusing on revascularisation, drug-eluting stents and antiplatelet therapies.
Journal of the American College of Cardiology | 2012
David M. Safley; James Grantham; Philip G. Jones; John A. Spertus
Methods: We leveraged a 10-center prospective registry of PCI patients consenting to health status assessments with the Seattle Angina Questionnaire (SAQ) at the time of PCI and in follow-up. After identifying all of the CTO PCIs attempted, we created propensity scores, based upon 40 variables, including demographic and clinical characteristics, baseline health status, procedure indication, diseased vessels and the specific coronary segments approached in order to match attempted CTO PCIs with up to 10 non-CTO PCIs. The primary analysis compared changes in SAQ Physical Limitation (PL), Quality of Life (QoL) and Angina Frequency (AF) scores as well as the Rose Dyspnea scores (RDS) between baseline and 6 months. The effect of CTO PCI on 6-month health status was estimated using mixed effect models, adjusting for matched sets and baseline health status. Non-inferiority was assessed for changes in health status scores between CTO and non-CTO PCI.
Catheterization and Cardiovascular Interventions | 2018
Matthew C. Bunte; David J. Cohen; Michael R. Jaff; William A. Gray; Elizabeth A. Magnuson; Haiyan Li; Andrew Feiring; Marco Cioppi; Robert Hibbard; Bruce H. Gray; Yazan Khatib; David B. Jessup; Roberto Patarca; Jing Du; Hans-Peter Stoll; Joe Massaro; David M. Safley; Stroll Study Investigators
To evaluate the clinical and health status outcomes of patients undergoing superficial femoral artery (SFA) revascularization using the Shape Memory Alloy Recoverable Technology (S.M.A.R.T.®) nitinol self‐expanding stent through 3 years of follow‐up.